Patents Issued in August 2, 2018
-
Publication number: 20180215810Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.Type: ApplicationFiled: March 22, 2018Publication date: August 2, 2018Applicant: Merck Sharp & Dahme Corp.Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
-
Publication number: 20180215811Abstract: Presented herein, in certain embodiments, are compositions comprising antibody binding agents that specifically bind to A. baumannii and inhibit and/or block A. baumannii infection, and uses thereof.Type: ApplicationFiled: July 13, 2016Publication date: August 2, 2018Applicant: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad SPELLBERG, Kevin BRUHN, Travis NIELSEN
-
Publication number: 20180215812Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.Type: ApplicationFiled: March 23, 2018Publication date: August 2, 2018Inventors: Julian NAGLIK, David MOYES, Shirley TANG, Bernhard HUBE, Duncan WILSON, Sarah HOFS, Jonathan RICHARDSON
-
Publication number: 20180215813Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20180215814Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20180215815Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20180215816Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20180215817Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.Type: ApplicationFiled: March 19, 2018Publication date: August 2, 2018Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
-
Publication number: 20180215818Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.Type: ApplicationFiled: November 22, 2017Publication date: August 2, 2018Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
-
Publication number: 20180215819Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).Type: ApplicationFiled: November 20, 2017Publication date: August 2, 2018Applicant: Janssen Biotech, Inc.Inventors: Diane D. Harrison, Elizabeth C. Hsia, Lee-Lian Kim, Kim Hung Lo
-
Publication number: 20180215820Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: ApplicationFiled: March 29, 2018Publication date: August 2, 2018Applicant: Kymab LimitedInventor: Jasper Rupert Clube
-
Publication number: 20180215821Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Applicant: XENCOR, INC.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Publication number: 20180215822Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: ApplicationFiled: February 9, 2018Publication date: August 2, 2018Applicant: XENCOR, INC.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Publication number: 20180215823Abstract: The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial.Type: ApplicationFiled: March 23, 2018Publication date: August 2, 2018Inventors: Eric Smith, Nicholas J. Papadopoulos
-
Publication number: 20180215824Abstract: The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab? antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.Type: ApplicationFiled: March 12, 2018Publication date: August 2, 2018Applicant: OSE ImmunotherapeuticsInventor: Bernard Vanhove
-
Publication number: 20180215825Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.Type: ApplicationFiled: July 1, 2015Publication date: August 2, 2018Inventors: Kang LI, Jing SONG, Tong ZHANG, Yucheng Li, Zhiying REN, Yanshen KANG
-
Publication number: 20180215826Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).Type: ApplicationFiled: December 19, 2017Publication date: August 2, 2018Inventor: Randolph J. Noelle
-
Publication number: 20180215827Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: December 5, 2017Publication date: August 2, 2018Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
-
Publication number: 20180215828Abstract: The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.Type: ApplicationFiled: March 27, 2018Publication date: August 2, 2018Inventors: Xiaoling LI, Jerry TSAI, Bhaskara Rao JASTI, Hyun JOO, Yu ZHENG, Dan SU, Sameer SACHDEVA
-
Publication number: 20180215829Abstract: Binding molecules that bind specifically to IL-17RA. The binding molecules are useful in the treatment of disease, for example psoriasis.Type: ApplicationFiled: January 12, 2016Publication date: August 2, 2018Inventors: Bryan EDWARDS, Ulla LASHMAR, Brian MCGUINNESS, Mike ROMANOS, Thomas SANDAL, Joyce Young
-
Publication number: 20180215830Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.Type: ApplicationFiled: March 26, 2018Publication date: August 2, 2018Applicant: Five Prime Therapeutics, Inc.Inventors: Justin Wong, Maximiliano Vasquez
-
Publication number: 20180215831Abstract: Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.Type: ApplicationFiled: July 27, 2016Publication date: August 2, 2018Inventors: Glen S. CHO, Brian SEED
-
Publication number: 20180215832Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: ApplicationFiled: January 11, 2018Publication date: August 2, 2018Inventors: MICHAEL TESAR, UTE JAGER
-
Publication number: 20180215833Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: December 26, 2017Publication date: August 2, 2018Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo MICHIELI, Cristina Basilico, Torsten DREIER
-
Publication number: 20180215834Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.Type: ApplicationFiled: June 26, 2017Publication date: August 2, 2018Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
-
Publication number: 20180215835Abstract: A protein includes an amino acid sequence derived from the sequence of SEQ ID NO: 1, wherein the amino acid sequence includes a substitution of Val at a position corresponding to position 40 of SEQ ID NO: 1 with a polar uncharged amino acid residue, a basic amino acid residue, or Ala. The protein has a reduced antibody-binding capacity in an acidic pH range, as compared to a protein including the amino acid sequence without the substitution.Type: ApplicationFiled: January 22, 2018Publication date: August 2, 2018Applicant: Kaneka CorporationInventors: Masakatsu Nishihachijyo, Yoshiyuki Nakano, Fuminori Konoike, Masayuki Takano, Shinichi Yoshida, Kazunobu Minakuchi
-
Publication number: 20180215836Abstract: A protein includes two or more amino acid sequences, wherein each amino acid sequence is derived from a sequence selected from the group consisting of SEQ ID NOs: 1 to 5. The amino acid sequence closest to the N-terminus includes more Lys residues than the other amino acid sequence(s), and in the amino acid sequence closest to the N-terminus, a total number of Lys in positions 1 to 38 is equal to or greater than a total number of Lys in position 39 and subsequent positions.Type: ApplicationFiled: January 30, 2018Publication date: August 2, 2018Applicant: Kaneka CorporationInventors: Masakatsu Nishihachijyo, Fuminori Konoike, Yoshiyuki Nakano, Masayuki Takano, Keita Yamashita
-
Publication number: 20180215837Abstract: Provided is a resin including both a structural unit derived from a monomer having a carbon-carbon double bond at a terminal thereof and a structural unit derived from a polyrotaxane compound, wherein the polyrotaxane compound is a compound substituted with a (meth)acryloyl group or a group containing a (meth)acryloyl group, the polyrotaxane includes optionally substituted cyclodextrin, a linear molecule clathrated in the optionally substituted cyclodextrin in a skewer shape, and a capping group for preventing the optionally substituted cyclodextrin from leaving, the capping group being located at a terminal of the linear molecule clathrated in the optionally substituted cyclodextrin in a skewer shape, and the weight average molecular weight of the linear molecule clathrated in the optionally substituted cyclodextrin in a skewer shape is greater than or equal to 21000 and less than or equal to 500000.Type: ApplicationFiled: July 20, 2016Publication date: August 2, 2018Inventors: Yoshinori SATO, Kenta ISHIZUKA
-
Publication number: 20180215838Abstract: A polydisperse inulin product has a factor L, defined as a ratio S/D, wherein: S equals the sum of the compounds GF2, F3, and F4 in the inulin product, expressed in wt. % on total carbohydrates; D equals [(Fi/Gi)+1], wherein Fi is the amount of inulin-related fructose in the inulin product, Gi is the amount of inulin-related glucose in the inulin product, whereby Fi and Gi are expressed in wt. % on total carbohydrates, wherein the value of L lies between 2.0 and 3.0 and wherein between 3 and 20 wt. % on total carbohydrates of the inulin product is: GFn compounds wherein n is 10 or greater, and/or Fm compounds wherein m is 11 or greater.Type: ApplicationFiled: August 3, 2016Publication date: August 2, 2018Inventor: Linda MERTENS
-
Publication number: 20180215839Abstract: The invention provides highly concentrated chitosan-nucleic acid polyplex compositions and dispersions, and methods for producing the compositions and dispersions. Methods of mixing the chitosan-nucleic acid polyplexes include an inline mixing of chitosan solution and nucleic acid solution, followed by further concentrating the dispersion of chitosan-nucleic acid polyplexes, optionally with an aggregation inhibitor. Further provides are methods for altering the diameter of chitosan-nucleic acid polyplexes.Type: ApplicationFiled: December 20, 2017Publication date: August 2, 2018Inventors: Eric HSU, Carlos Fleet, Anthony CHEUNG, Jun GAO
-
Publication number: 20180215840Abstract: Provided are a method of preparing a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, including cross-linking hyaluronic acid with an epoxy-based cross-linking agent having at least two epoxy functional groups in an ethanol-containing aqueous alkaline; a method of preparing a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, including cross-linking the same cross-linked hyaluronic acid with the same epoxy-based cross-linking agent in an aqueous alkaline solution; and a combination of the cross-linked hyaluronic acids one having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa and the other having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa.Type: ApplicationFiled: June 1, 2016Publication date: August 2, 2018Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Chul CHOI, Hyun Il KIM, Ki Young YANG, Hyo Seung PARK, Back Ho LEE
-
Publication number: 20180215841Abstract: A method for preparing an improved gum arabic comprising the steps of providing a gum arabic from acacia seyal selecting gum arabic having a tannin content >700 ppm (w/w).Type: ApplicationFiled: July 29, 2016Publication date: August 2, 2018Applicant: DÖHLER GMBHInventors: Saphwan Al-Assaf, Johann Lukanowski, Joachim Tretzel
-
Publication number: 20180215842Abstract: An adhesive composition comprising (a) a (meth)acrylic polymer, (b) a compound having at least two (meth)acryloyl groups, (c) a polymerization initiator and (d) a filler.Type: ApplicationFiled: July 27, 2016Publication date: August 2, 2018Inventors: Sadaaki KATOU, Takuya KOMINE, Shinjiro FUJII
-
Publication number: 20180215843Abstract: An optical film including: a cholesteric layer of a disk-like liquid crystal composition including a disk-like liquid crystal compound, in which the cholesteric layer exhibits a cholesteric liquid crystalline phase, and in which fluctuation of a helical pitch in a film thickness direction of the cholesteric layer is 2% or greater, and having a cholesteric liquid crystalline phase of a disk-like liquid crystal compound and a wide reflection bandwidth; a brightness enhancement film; a backlight unit with a brightness enhancement film; and a liquid crystal display device.Type: ApplicationFiled: March 29, 2018Publication date: August 2, 2018Applicant: FUJIFILM CorporationInventors: Wataru HOSHINO, Yukito SAITOH, Kunihiro ATSUMI
-
Publication number: 20180215844Abstract: A functionalized polymer can be prepared by a process that includes reacting (a) an ethylenically unsaturated reactant polymer which, at its terminus, includes Si-containing repeat unit(s) with (b) one or more silanes, at least one of which includes at least one primary amine, secondary amine, phosphine, hydroxyl, thiol, cyano, urea or thiourea group.Type: ApplicationFiled: July 22, 2016Publication date: August 2, 2018Applicant: Bridgestone CorporationInventor: Yuan-Yong YAN
-
Publication number: 20180215845Abstract: A gas-phase process for the homopolymerization or copolymerization of propylene with other olefins, including carrying out the polymerization in the presence of a catalyst system made from or containing: (a) a solid catalyst component made from or containing Mg, Ti, halogen, an electron donor selected from 1.3-diethers and an olefin polymer in a specific amount; (b) an aluminum alkyl compound and (c) an external electron donor (ED) compound, wherein components (b) and (c) being employed in amounts such that the Al/(ED) molar ratio ranges from about 2 to about 200.Type: ApplicationFiled: August 3, 2016Publication date: August 2, 2018Applicant: BASELL POLIOLEFINE ITALIA S.R.L.Inventors: GIAMPIERO MORINI, MASSIMO COVEZZI, TIZIANO DALL'OCCO, DARIO LIGUORI, FABRIZIO PIEMONTESI, GIANNI VITALE
-
Publication number: 20180215846Abstract: The invention is related to a composition of polypropylene and polyethylene, which contains specific compatibilizer and flow enhancer. Furthermore the present invention is also related to articles comprising the said composition and the use of said articles in packaging application.Type: ApplicationFiled: November 3, 2016Publication date: August 2, 2018Applicant: BOREALIS AGInventors: Bhawna Kulshreshtha, Markus Gahleitner
-
Publication number: 20180215847Abstract: The present invention provides, inter alia, a process for incorporating a cyclopropenium ion into a polymeric system. Processes for making cross-linked polymers, linear polymers, and dendritic polymers, as well as for incorporating a cyclopropenium ion onto a preformed polymer are also provided. Further provided are stable, polycationic compounds, various polymers that contain stable cyclopropenium cations, and substrates containing such polymers. The use of these polymers in water purification systems, antimicrobial coatings, ion-transport membranes, cell supports, drug delivery vehicles, and gene therapeutic vectors are also provided.Type: ApplicationFiled: August 14, 2017Publication date: August 2, 2018Inventors: TRISTAN HAYES LAMBERT, LUIS M. CAMPOS, JEFFREY BANDAR, EMMA JANE DELL
-
Publication number: 20180215848Abstract: The non-fluorinated polymer includes a constituent unit derived from a (meth)acrylic acid ester monomer (A) represented by the following General Formula (A-1); and at least one monomer (E) from between vinyl chloride and vinylidene chloride: wherein in Formula (A-1), R1 represents a hydrogen or a methyl group; and R2 represents a monovalent hydrocarbon group having 12 or more carbon atoms which may have a substituent.Type: ApplicationFiled: July 13, 2016Publication date: August 2, 2018Inventors: Masaaki HOSODA, Makoto NISHIKAWA, Min-Si JUNG
-
Publication number: 20180215849Abstract: This invention relates to segment copolymer comprising rigid and soft segments wherein the soft segments are doped with a wax. A model polymer of this new type can be synthesized by the free radical copolymerization of methyl methacrylate (MMA) (39 wt %), lauryl, methacrylate (LMA) (10 wt %) and an adduct monomer of glycidyl methacrylate (GMA) and 1-dodecylamine (DDA). Doping with paraffin wax is one suitable approach to obtain the inventive material. The invention further relates to a simple and low-cost process to make these polymers and coatings comprising the polymers. Using the polymer material a coating with a highly icephobic surface can be obtained comprising soft hydrophobic micro domains segregated and stabilized by rigid copolymer on its surface. The icephobic behaviour may find new application in aerospace applications.Type: ApplicationFiled: January 29, 2018Publication date: August 2, 2018Inventors: Liang HONG, Siok Wei TAY, Yeap Hung NG
-
Publication number: 20180215850Abstract: The present invention relates to a photocurable resin composition usable in a nanoimprint process which is capable of overcoming low productivity of conventional semiconductor processes for optical devices and electronic devices, and a method of forming patterns using the same. Specifically, the present invention relates to a photocurable resin composition including a specific perfluorinated acrylic compound for improving release property between a nanoimprint mold and the photocurable resin composition, and a method of forming patterns using the same.Type: ApplicationFiled: October 5, 2016Publication date: August 2, 2018Inventors: Hyung-Jong LEE, Nam Seob BAEK, Jonghwi LEE, Yun Jung SEO, Hyun Jin YOO
-
Publication number: 20180215851Abstract: The present disclosure provides a peroxide-modified polyethylene, related compositions, and wire-and-cable products made therefrom. The process for preparing the peroxide-modified polyethylene including the steps of: (A) preparing a first Ziegler-Natta-catalyzed polyethylene in a first reactor; (B) transferring the first Ziegler-Natta-catalyzed polyethylene from the first reactor to a second reactor; (C) admixing a first amount of an organic peroxide to the second reactor; (D) reacting the organic peroxide with a polyethylene composition made from or containing the first Ziegler-Natta-catalyzed polyethylene, thereby coupling the polyethylene components and forming the peroxide-modified polyethylene; and (E) collecting the peroxide-modified polyethylene.Type: ApplicationFiled: January 25, 2018Publication date: August 2, 2018Applicant: EQUISTAR CHEMICALS, LPInventors: CHUN D. LEE, MICK C. HUNDLEY, CINDY FLENNIKEN
-
Publication number: 20180215852Abstract: This invention relates to monodisperse cross-linked hydrogel polymer particles comprising a polymer formed from (a) a hydrophilic vinylic monomer; and (b) a crosslinker comprising at least two vinyl groups. The invention also relates to monodisperse seed particles with a Z-average diameter of from 100 nm to 1500 nm that comprise a plurality of non-crosslinked oligomers of poly N,N-dimethylacrylamide. Also provided are methods of forming the monodisperse cross-linked hydrogel polymer particles and monodisperse seed particles.Type: ApplicationFiled: July 19, 2016Publication date: August 2, 2018Applicant: SINTEFInventors: Geir FONNUM, Nils LUNDBERG, Muhammed GOKMEN, Synne LARSEN, Wilhelm Glomm, Heidi Johnsen, Ruth SCHMID, Lars Kilaas
-
Publication number: 20180215853Abstract: A curable composition for making polyisocyanurate comprising products obtained by combining and mixing at an isocyanate index of at least 100 at least a polyisocyanate composition, a polytetrahydrofuran polyol (P-THF) having average molecular weight in range 1000-5000 g/mol as toughening agent and diols having an average molecular weight <1000 g/mol.Type: ApplicationFiled: May 26, 2016Publication date: August 2, 2018Inventor: Andre Steve Woutters
-
Publication number: 20180215854Abstract: A method for producing a bonded permanent magnet by additive manufacturing, the method comprising: (i) incorporating components of a reactive precursor material into an additive manufacturing device, the reactive precursor material comprising an amine component, an isocyanate component, and particles having a permanent magnetic composition; and (ii) mixing and extruding the crosslinkable reactive precursor material through a nozzle of the additive manufacturing device and depositing the extrudate onto a substrate under conditions where the extrudate is permitted to cure, to produce a bonded permanent magnet of desired shape. The resulting bonded permanent magnet and articles made thereof are also described.Type: ApplicationFiled: February 2, 2018Publication date: August 2, 2018Inventors: M. Parans PARANTHAMAN, Orlando RIOS, William G. CARTER, David FENN, Cajetan Ikenna NLEBEDIM
-
Publication number: 20180215855Abstract: A method for making a copolymer polyol includes (a) forming a pre-compounded thermoplastic polymeric composition by compounding from 10 wt % to 90 wt % of a solid functional additive component with from 10 wt % to 90 wt % of a polystyrene component, (b) melting the pre-compounded thermoplastic polymeric composition to form a melted thermoplastic polymeric composition, (c) combining the melted thermoplastic polymeric composition with a carrier polyol component in the presence of a stabilizer component to form a pre-mixture that includes the pre-compounded thermoplastic polymeric composition dispersed within a continuous phase of the carrier polyol component, and (d) cooling the pre-mixture to form the copolymer polyol.Type: ApplicationFiled: September 7, 2016Publication date: August 2, 2018Applicant: Dow Global Technologies LLCInventors: Hanno R. Van der Wal, Paul Cookson, Francois M. Casati, Antoon De Smet, Sven Claessens, Prashant Tatake, Bart Noordover, Brian Anthony, Jozef Van Dun
-
Publication number: 20180215856Abstract: The present invention relates to novel associative thickeners pertaining to the HEUR category (Hydrophobically-modified Ethoxylated URethane), to intermediate aqueous formulations containing such thickeners, and to the final compositions, for example paint, lacquer, varnish or paper coating slip compositions.Type: ApplicationFiled: August 3, 2016Publication date: August 2, 2018Applicant: COATEXInventors: Denis RUHLMANN, Catherine CORFIAS ZUCCALLI, Jean-Marc SUAU, Yves MATTER, Benoit MAGNY
-
GUANYLUREA ALCOHOL PHOSPHATES AND THEIR USE AS REACTANTS IN POLYURETHANE AND EPOXY RESIN APPICATIONS
Publication number: 20180215857Abstract: Guanylurea alcohol phosphate salts are disclosed. Flame retardant thermoplastic and thermoset polymers can be made by incorporating said guanylurea alcohol phosphate salts into polymers and these polymers have improved properties over similar thermoplastic or thermoset polymers where guanylurea phosphate salts are added as flame retardant dispersions to said polymer. Flame retardant polyurethane foams where the guanylurea alcohol phosphate salts have been incorporated into the polyurethane are a particularly preferred embodiment.Type: ApplicationFiled: July 26, 2016Publication date: August 2, 2018Inventors: John Ta-Yuan Lai, Janean Nagorski -
Publication number: 20180215858Abstract: Some embodiments are directed to a fire-resistant polyurethane material including a plurality of polyol reactive elements and a plurality of diisocyanate reactive elements and at least one diamine or diol reactive element operating as a chain extender of the polyurethane. A chain extender of at least the polyurethane material includes a phosphorous-containing oligomer element of a predefined length having a value within a dispersion interval, which is also predefined. Some embodiments also relate to polyurethanes obtained by implementing the method.Type: ApplicationFiled: July 13, 2016Publication date: August 2, 2018Inventors: Jean-François PILARD, Arnaud NOURRY, Krishna Veni BARATHA NESAN
-
Publication number: 20180215859Abstract: The invention relates to a method for producing a biomass-resource-derived polyurethane, which comprises: reacting a dicarboxylic acid and an aliphatic diol to produce a polyester polyol; and reacting the polyester polyol and a polyisocyanate compound, wherein the dicarboxylic acid contains at least one component derived from biomass resources, a content of an organic acid in the dicarboxylic acid is more than 0 ppm and not more than 1,000 ppm relative to the dicarboxylic acid, and a pKa value of the organic acid at 25° C. is not more than 3.7.Type: ApplicationFiled: March 27, 2018Publication date: August 2, 2018Applicant: Mitsubishi Chemical CorporationInventors: Teruhiko OHARA, Naoki SUZUKI, Yasuko NAKAJIMA, Hiroto ITOU, Takayuki AOSHIMA, Naoki SUGAI, Takanao MATSUMOTO